Dysregulation of the IGF-1 signaling pathway, facilitated by its isoforms IGF-1Ea, IGF-1Eb, and IGF-1Ec, has been implicated in promoting oncogenic phenotypes and contributing to therapeutic resistance in BC [7,18]. This evidence concerns the gene IGF1 and breast cancer.